BioArctic and Eisai: clinical trial on BAN2401
BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are thought to
Elsevier Acquires 3D4Medical, Creator of World-leading 3D Anatomy Technology
Elsevier, a global information analytics business specializing in science and health, and part of RELX, has acquired 3D4Medical, the global anatomy education company headquartered in Dublin, Ireland. 3D4Medical created Complete Anatomy, the world's most advanced 3D anatomy platform, revolutionizing how students,
TauRx : Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-moderate Alzheimer’s Disease
TauRx has reportedunexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease. These results showed that, even at
Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre
Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing $1.9 million, is part of a long-term investment strategy to grow its share of the Microbial Biopharma CDMO
Y-mAbs Initiates Rolling Submission of Biologics License Application to FDA for Naxitamab for Treatment of Neuroblastoma
Y-mAbs Therapeutics, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) the first portions of
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for spinal muscular
Celularity: Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in Glioblastoma
Celularity, a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion
The Medicines Company announced that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7 billion. The price represents
FDA grants Breakthrough Therapy Designation to psilocybin program for major depressive disorder
Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatmentof major depressive disorder (MDD). Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in
Azeria Therapeutics Announces £32.0 Million Series B Financing
Azeria Therapeutics, a newly formed pioneer factor drug discovery company, announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund. Azeria was originally founded in 2017 by Sixth Element